LINICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 408 JPY | +0.25% |
|
+2.26% | -23.02% |
| Sales 2024 * | 12.28B 78.91M | Sales 2025 * | 12.3B 79.04M | Capitalization | 9.22B 59.22M |
|---|---|---|---|---|---|
| Net income 2024 * | 307M 1.97M | Net income 2025 * | 400M 2.57M | EV / Sales 2024 * | 0.43 x |
| Net cash position 2024 * | 3.93B 25.24M | Net cash position 2025 * | 4.33B 27.81M | EV / Sales 2025 * | 0.4 x |
| P/E ratio 2024 * |
30
x | P/E ratio 2025 * |
30
x | Employees | 759 |
| Yield 2024 * |
3.68% | Yield 2025 * |
3.68% | Free-Float | 45.77% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.25% | ||
| 1 week | +2.26% | ||
| Current month | +3.55% | ||
| 1 month | +1.49% | ||
| 3 months | -23.02% | ||
| 6 months | -29.53% | ||
| Current year | -23.02% |
1 week
390.00
408.00
1 month
379.00427.00
Current year
374.00553.00
1 year
374.00874.00
3 years
374.001 029.00
5 years
374.001 379.00
10 years
374.002 584.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kazuhiro Hatano
FOU | Founder | 59 | 05-06-06 |
| Director of Finance/CFO | 56 | 05-06-06 | |
Shiori Yamaguchi
CMP | Compliance Officer | 48 | 05-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tomoko Nishimura
BRD | Director/Board Member | - | - |
Kazuhiro Hatano
FOU | Founder | 59 | 05-06-06 |
| Director of Finance/CFO | 56 | 05-06-06 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 19 M€ | +2.79% | ||
| 0.00% | 18 M€ | +16.15% | - | |
| 0.00% | 144,586 M€ | +13.76% | ||
| 0.00% | 66,066 M€ | +13.80% | - | |
| 0.00% | 20,721 M€ | +12.65% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 408 | +0.25% | 23 000 |
| 24-04-24 | 407 | +2.26% | 37,200 |
| 24-04-23 | 398 | +0.51% | 15,600 |
| 24-04-22 | 396 | +1.54% | 29,500 |
| 24-04-19 | 390 | -2.26% | 45,400 |
Delayed Quote Japan Exchange, April 25, 2024 at 02:00 am EDT
More quotes
Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.
Calendar
2024-05-14
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
408
JPY
Average target price
500
JPY
Spread / Average Target
+22.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.02% | 59.28M | |
| +0.81% | 43.84B | |
| +5.19% | 41.68B | |
| +45.21% | 41.25B | |
| -10.92% | 27.04B | |
| +7.36% | 25.53B | |
| -25.72% | 18.18B | |
| -4.08% | 12.29B | |
| +24.78% | 12.29B | |
| +6.82% | 11.15B |
- Stock Market
- Equities
- 2183 Stock
